Intarcia Therapeutics inks a development deal worth more than $1 billion with French pharmaceutical company Servier to develop its implantable drug pump for treating Type II diabetes.
Intarcia Therapeutics said today that French pharmaceutical independent Servier agreed to a deal to commercialize Intarcia's implantable diabetes pump that could be worth some $1 billion.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1v3aYXN
Cap comentari:
Publica un comentari a l'entrada